In South Korea, 19 pharmaceutical companies have obtained marketing approval for generic drugs of MSD’s Bridion (sugammadex). In addition, Korean pharma companies Celltrion, Dongbang and Hanmi Pharmaceutical, will be supplying generic COVID-19 drugs to middle- and low-income countries.
Bridion is a muscle relaxation antagonist used to bring people round following anaesthesia [1]. It first became available in South Korea in 2013 and now, in April 2022, the originator patent expires, opening up the market for generics entry. Although a number of companies attempted to invalidate MSD’s patent (previously Merck) and receive a period of generic market exclusivity, none were successful; and the Korean market is now open to all approved products. Companies due to enter the market include CTC Bio Intro Bio Pharma, Hana Pharm, Huons Global, and Chong Kun Dang, all of which filed suits to invalidate the originator patent.
It has also been announced that Celltrion, Dongbang and Hanmi will develop and produce generic COVID-19 therapy drugs and supply them to 95 low- and medium- income countries under the terms of the contract with the United Nations (UN)-backed Medicine Patent Pool (MPP).
Celltrion signed a contract with the UN MPP for the generic production of Pfizer’s oral COVID-19 treatment, Paxlovid [2]. In addition, Celltrion, Dongbang and Hanmi are all now able to produce and supply generic drugs after securing a licence for MSD’s oral COVID-19 treatment, molnupiravir which is also included in the UN MPP [2].
Celltrion has previously been investigating the use of its infliximab biosimilar to treat patients with COVID-19 infection [3].
Related articles
Pfizer and Merck COVID-19 antiviral progress
Merck partners with Indian drugmakers to increase access to COVID-19 drug
Biosimilar advances for Celltrion Healthcare
| LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Biocomparables aprobados en México Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Biocomparables aprobados en México !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Merck to create spin-off for women’s health and biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from: www.gabionline.net/pharma-news/Merck-to-create-spin-off-for-women-s-health-and-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. MPP agreements allow generics production of Merck and Pfizer’s COVID-19 treatments [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from:
www.gabionline.net/generics/general/mpp-agreements-allow-generics-production-of-merck-and-pfizer-s-covid-19-treatments
3. GaBI Online - Generics and Biosimilars Initiative. Biocon and Celltrion make progress in the battle against COVID-19 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Apr 15]. Available from: www.gabionline.net/biosimilars/news/Biocon-and-Celltrion-make-progress-in-the-battle-against-COVID-19
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment